首頁 > 市場調查報告書 > 醫療設備

體外診斷生技設備

市場調查報告書

商品編碼

2126353

消化器官系統病原體診斷市場：策略性洞察與預測（2026-2035 年）

Gastrointestinal Pathogen Diagnostics Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月05日 | 出版商:

Knowledge Sourcing Intelligence | 英文 174 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計消化器官系統病原體診斷市場將從 2026 年的 93.3 億美元成長到 2035 年的 205.5 億美元，複合年成長率為 9.2%。

消化器官系統病原體診斷市場正經歷一場重大變革，其驅動力在於多重分子診斷和基於症候群的檢測模式轉移。這一市場演變的特點是，人們日益認知到快速準確地識別致病病原體對於改善患者管理、減少不必要的治療以及加強對疫情的應對至關重要。多重PCR檢測、次世代定序和自動化檢測系統等先進分子技術的融合，使得病原體檢測更快速、更全面且日益普及。由於多種病原體可能表現出相似的臨床症狀，基於症狀的診斷往往缺乏特異性，因此醫療系統需要擴大診斷檢測範圍。疾病監測計畫依賴消化器官系統病原體檢測，因為快速檢測和流行病學監測對於感染疾病爆發至關重要。監管持續影響市場發展，因為診斷的可靠性直接影響治療策略和監測結果。目前，多重分子檢測板、基於症候群的檢測平台和數位報告解決方案都得到了大量投資，胃腸道病原體診斷正在成為感染疾病控制和公共衛生準備的重要組成部分。

市場促進因素

食物中毒和傳染性胃腸道疾病負擔的日益加重是胃腸道病原體診斷市場的主要促進因素。由於傳染性胃腸道疾病持續給全球醫療保健帶來沉重負擔，胃腸道病原體診斷仍然至關重要。隨著醫療保健機構尋求早期識別致病病原體以控制疾病傳播並改善患者預後，對檢測的需求不斷成長。診斷延誤會限制臨床介入的有效性，並增加不必要的治療可能性。醫療保健系統正在透過引入分子檢測和加強監測系統來擴展其診斷能力，從而推動胃腸道病原體診斷的持續成長。多重分子診斷檢測的擴展透過實現病原體的全面檢測，進一步加速了市場成長。多重分子診斷可在單一檢測流程中涵蓋多種病原體。由於胃腸道感染疾病中經常出現重疊的臨床症狀，使診斷變得複雜，因此醫療保健專業人員擴大採用多重檢測平台。順序檢測方法會導致更長的檢測時間和更高的檢查室成本。診斷設備製造商正在開發高通量分子檢測方法，以提高工作流程效率並維持分析效能。這一轉變促進了先進診斷技術的廣泛應用。加強食品安全和疾病監測計畫正在增加檢查室檢測量和基礎設施投資。公共衛生機構依靠快速病原體檢測來支持疫情調查和疾病控制。各國政府正在加大對監測基礎設施的投資，因為及時干預和準確的流行病學數據對於應對食物中毒疫情至關重要。有限的檢測能力使得追蹤疾病傳播途徑變得困難，並延誤了公共衛生反應。醫療機構正在擴展其分子檢測能力，以提高監測的有效性和報告品質。這一趨勢正在推動整個公共衛生網路的診斷需求。隨著人們對合理使用抗生素的關注度不斷提高，胃腸道病原體診斷的臨床價值也不斷提升。準確鑑定病原體對於選擇合適的治療方案至關重要，因為細菌、病毒和寄生蟲感染疾病的治療方法各不相同。醫療服務提供者擴大使用診斷測試來減少不必要的抗生素暴露並提高治療的準確性。

市場限制因素

多分子診斷平台的高昂實施和營運成本阻礙了資源匱乏的檢查室採用這些平台。先進平台所需的大量資金投入對小規模機構而言是一大障礙。不同醫療體系報銷率的差異抑制了對先進胃腸道病原體檢測技術的投資。保險覆蓋範圍的區域差異給診斷服務提供者帶來不確定性，並限制了患者的就醫途徑。在某些地區，檢查室基礎設施和熟練人員的匱乏限制了先進分子診斷工作流程的採用。專業檢查室和人員的缺乏限制了先進診斷技術的普及。複雜且區域差異顯著的法規給尋求將新型診斷解決方案商業化的製造商帶來了合規負擔。

市場定義和範圍
胃腸道感染疾病概述
消化器官系統病原體診斷技術的演變
主要市場趨勢
疾病負擔與未滿足的診斷需求
全球胃腸道感染疾病的流行情況
已確診患者族群的分析
測試數量分析
目前診斷和臨床管理狀況
病人歷程分析
市場規模表現分析
市場預測分析

第4章市場動態

市場促進因素
市場限制因素
市場機遇
市場挑戰

第5章行業情勢

產業價值鏈分析
定價分析
還款狀態

第6章：創新趨勢

消化器官系統病原體診斷領域的新興技術
產品創新趨勢
臨床試驗分析
管道分析
症候群檢測進展
整合次世代定序
人工智慧和生物資訊學的應用
技術藍圖

第7章監理情勢

法律規範
核准流程
合規要求

第8章：消化器官系統病原體診斷市場：展望分析

分析：按技術平台
分析：依病原體類型
分析：檢體類型
分析：透過臨床應用
分析：透過測試方法
分析：按最終使用者環境

第9章：消化器官系統病原體診斷市場：細分市場分析

依產品類型
- 裝置
- 試劑和耗材
- 軟體和診斷分析解決方案
透過技術
- 多重PCR檢測板
- 聚合酵素鏈鎖反應（PCR）
- 免疫測量
- 基於培養方法的診斷
- 次世代定序（NGS）
- 快速診斷測試
- 其他分子診斷技術
依病原體類型
- 細菌病原體
- 病毒病原體
- 寄生病原體
依檢體類型
- 糞便檢體
- 直腸拭子
- 切片檢查檢體
- 其他消化器官系統檢體
最終用戶
- 醫院
- 臨床實驗室
- 參考實驗室
- 學術研究機構
- 公共衛生研究所

第10章：消化器官系統病原體診斷市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章：消化器官系統病原體診斷市場：國家分析

美國
加拿大
德國
英國
法國
義大利
西班牙
荷蘭
中國
日本
印度
韓國
澳洲
巴西
沙烏地阿拉伯

第12章競爭格局

市佔率分析
策略趨勢
併購、合作與聯盟
新產品發布

第13章：公司簡介

bioMerieux SA
QIAGEN NV
Danaher Corporation（Cepheid）
Abbott Laboratories
F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific Inc.
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.
Seegene Inc.
Sysmex Corporation
Revvity, Inc.
Meridian Bioscience, Inc.
Luminex Corporation
DiaSorin SpA
Siemens Healthineers AG

第14章：消化器官系統病原體診斷市場：商業預測分析

第15章：投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009064

The Gastrointestinal pathogen diagnostics market is anticipated to grow at a CAGR of 9.2% from USD 9.33 billion in 2026 to USD 20.55 billion in 2035.

The gastrointestinal pathogen diagnostics market is undergoing significant transformation driven by the paradigm shift toward multiplex molecular diagnostics and syndromic testing. The market's evolution is characterized by the growing recognition that rapid and accurate identification of causative pathogens is essential for improving patient management, reducing unnecessary treatment utilization, and strengthening outbreak response. The convergence of advanced molecular technologies, including multiplex PCR panels, next-generation sequencing, and automated laboratory systems, is enabling faster, more comprehensive, and increasingly accessible pathogen detection. Healthcare systems are expanding diagnostic testing because symptom-based diagnosis often lacks specificity, as multiple pathogens can present with similar clinical manifestations. Disease surveillance programs depend on gastrointestinal pathogen testing because infectious outbreaks require timely detection and epidemiological monitoring. Regulatory oversight continues shaping market development because diagnostic reliability directly affects treatment decisions and surveillance outcomes. The market is witnessing significant investment in multiplex molecular panels, syndromic testing platforms, and digital reporting solutions, positioning gastrointestinal pathogen diagnostics as a critical component of infectious disease management and public health preparedness.

Market Drivers

The rising burden of foodborne and infectious gastrointestinal diseases represents the primary driver for the gastrointestinal pathogen diagnostics market. Gastrointestinal pathogen diagnostics remain essential because infectious gastrointestinal diseases continue creating substantial healthcare burdens worldwide. Testing demand is increasing as healthcare providers seek earlier identification of causative pathogens to reduce disease transmission and improve patient outcomes. Delayed diagnosis limits the effectiveness of clinical intervention and increases the likelihood of unnecessary treatment utilization. Healthcare systems are expanding diagnostic capacity through molecular testing adoption and enhanced surveillance initiatives, resulting in sustained growth in gastrointestinal pathogen diagnostic utilization. The expansion of multiplex molecular diagnostic testing is further accelerating market growth by enabling comprehensive pathogen detection. Multiplex molecular diagnostics provide broad pathogen coverage within a single testing workflow. Healthcare providers are increasingly adopting multiplex platforms because gastrointestinal infections frequently involve overlapping clinical symptoms that complicate diagnosis. Sequential testing approaches extend turnaround times and increase laboratory costs. Diagnostic manufacturers are developing high-throughput molecular assays that improve workflow efficiency while maintaining analytical performance. This transition supports increasing adoption of advanced diagnostic technologies. Strengthening food safety and disease surveillance programs is increasing laboratory testing volumes and infrastructure investment. Public health agencies depend on rapid pathogen detection to support outbreak investigations and disease control measures. Governments are increasing investments in surveillance infrastructure because foodborne disease outbreaks require timely intervention and accurate epidemiological data. Limited testing capacity reduces visibility into disease transmission patterns and delays public health responses. Healthcare organizations are expanding molecular testing capabilities that improve surveillance effectiveness and reporting quality. This development reinforces diagnostic demand across public health networks. The increasing focus on antimicrobial stewardship is strengthening the clinical value of gastrointestinal pathogen diagnostics. Appropriate treatment selection depends on accurate pathogen identification because bacterial, viral, and parasitic infections require different management approaches. Healthcare providers are increasingly utilizing diagnostic testing to reduce unnecessary antimicrobial exposure and improve therapeutic precision.

Market Restraints

High acquisition and operating costs associated with multiplex molecular diagnostic platforms limit adoption among resource-constrained laboratories. The significant financial investment required for advanced platforms creates barriers for smaller facilities. Reimbursement variability across healthcare systems reduces investment incentives for advanced gastrointestinal pathogen testing technologies. Inconsistent coverage across regions creates uncertainty for diagnostic providers and limits patient access. Limited laboratory infrastructure and skilled personnel restrict implementation of sophisticated molecular diagnostic workflows in certain regions. The shortage of specialized laboratories and workforce limits the scalability of advanced diagnostics. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new diagnostic solutions.

Technology and Segment Insights

The technology landscape is characterized by the growing importance of multiplex molecular diagnostics and syndromic testing platforms. Multiplex PCR panels are becoming a preferred diagnostic approach because they enable simultaneous detection of multiple gastrointestinal pathogens from a single sample. Demand is increasing as healthcare providers seek faster and more comprehensive diagnostic information. PCR remains the foundational technology for molecular detection. Immunoassays continue supporting rapid antigen testing. Culture-based diagnostics remain important for organism isolation and antimicrobial susceptibility testing. NGS is emerging for genomic surveillance and outbreak investigation. The segment analysis reveals that bacterial pathogen testing generates substantial demand because bacterial gastroenteritis remains a major cause of healthcare utilization and foodborne disease outbreaks. Healthcare providers increasingly require rapid identification of causative organisms to support targeted treatment and outbreak response activities. Viral pathogens, including norovirus and rotavirus, represent significant testing targets. Parasitic pathogens remain important in endemic regions and among immunocompromised populations. Stool samples constitute the primary specimen type for gastrointestinal pathogen testing. Hospitals represent the leading end-user segment, with clinical diagnostic laboratories and public health laboratories expanding testing capacity. The integration of digital surveillance and reporting systems is becoming increasingly important because disease control programs depend on efficient communication of diagnostic information. Technology providers are integrating diagnostic platforms with automated reporting and analytics capabilities that improve public health responsiveness.

Competitive and Strategic Outlook

The competitive landscape features established diagnostics and life science companies alongside specialized molecular and syndromic testing providers. bioMerieux is strategically distinct because it combines infectious disease expertise, syndromic testing leadership, and advanced laboratory informatics capabilities within a unified diagnostic ecosystem, expanding utilization of the BIOFIRE platform which supports rapid syndromic gastrointestinal testing and broad pathogen coverage. QIAGEN differentiates itself through its expertise in molecular diagnostics, sample preparation technologies, and bioinformatics solutions that support infectious disease testing, strengthening molecular testing workflows that improve sensitivity while supporting operational efficiency. Danaher, through Cepheid, is strategically distinct because it provides rapid molecular testing platforms that support both centralized and decentralized diagnostic environments, advancing cartridge-based molecular diagnostics that simplify testing while maintaining high analytical performance. Abbott maintains a strong position because it combines global diagnostic scale, extensive infectious disease expertise, and broad healthcare market access, expanding molecular diagnostic capabilities that improve pathogen detection while supporting operational efficiency. Roche is strategically distinct because of its leadership in molecular diagnostics and infectious disease testing, expanding molecular diagnostic capabilities that improve pathogen detection and laboratory productivity. Thermo Fisher Scientific occupies a strategically important position because it combines molecular diagnostics, life science technologies, laboratory instruments, and bioinformatics capabilities, investing in molecular testing solutions and workflow automation that improve laboratory productivity. BD differentiates itself through expertise in microbiology, specimen management, and laboratory workflow optimization, strengthening automation and laboratory integration capabilities that improve efficiency. Companies are pursuing product portfolio expansion through innovation in multiplex molecular panels, syndromic testing platforms, and digital reporting solutions. Strategic collaborations between diagnostic manufacturers and public health organizations are increasing, driven by the need for surveillance and outbreak response. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

The gastrointestinal pathogen diagnostics market is positioned for sustained growth driven by the convergence of foodborne disease burden, multiplex molecular diagnostics, and public health surveillance. The transition from conventional culture-based methods toward integrated molecular and syndromic testing platforms represents a fundamental evolution in infectious disease diagnostics. While challenges related to high costs, reimbursement variability, and infrastructure limitations persist, strategic investments in technology, automation, and partnerships are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with gastrointestinal pathogen diagnostics evolving into a critical component of infectious disease management and public health preparedness, supporting rapid pathogen identification, outbreak response, and surveillance across global healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Gastrointestinal Pathogen Diagnostics Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Gastrointestinal Infectious Diseases Overview
3.3 Evolution of Gastrointestinal Pathogen Diagnostic Technologies
3.4 Key Market Trends
3.5 Disease Burden and Unmet Diagnostic Needs
3.6 Global Prevalence of Gastrointestinal Infections
3.7 Diagnosed Patient Population Analysis
3.8 Testing Volume Analysis
3.9 Current Diagnostic and Clinical Management Landscape
3.10 Patient Journey Analysis
3.11 Historical Market Size Analysis (2021-2025)
3.12 Market Forecast Analysis (2026-2035)

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Technologies in Gastrointestinal Pathogen Diagnostics
6.2 Product Innovation Trends
6.3 Clinical Trial Analysis
6.4 Pipeline Analysis
6.5 Syndromic Panel Testing Developments
6.6 Next-Generation Sequencing Integration
6.7 AI and Bioinformatics Applications
6.8 Technology Roadmap

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Gastrointestinal Pathogen Diagnostics Market Landscape Analysis

8.1 Analysis by Technology Platform
8.2 Analysis by Pathogen Type
8.3 Analysis by Sample Type
8.4 Analysis by Clinical Application
8.5 Analysis by Testing Methodology
8.6 Analysis by End-user Environment

9. Gastrointestinal Pathogen Diagnostics Market Segment Analysis (2021-2035)

9.1 By Product Type
- 9.1.1 Instruments
- 9.1.2 Reagents & Consumables
- 9.1.3 Software & Diagnostic Analytics Solutions
9.2 By Technology
- 9.2.1 Multiplex PCR Panels
- 9.2.2 Polymerase Chain Reaction (PCR)
- 9.2.3 Immunoassays
- 9.2.4 Culture-Based Diagnostics
- 9.2.5 Next-Generation Sequencing (NGS)
- 9.2.6 Rapid Diagnostic Tests
- 9.2.7 Other Molecular Diagnostic Technologies
9.3 By Pathogen Type
- 9.3.1 Bacterial Pathogens
- 9.3.2 Viral Pathogens
- 9.3.3 Parasitic Pathogens
9.4 By Sample Type
- 9.4.1 Stool Samples
- 9.4.2 Rectal Swabs
- 9.4.3 Biopsy Samples
- 9.4.4 Other Gastrointestinal Samples
9.5 By End User
- 9.5.1 Hospitals
- 9.5.2 Clinical Diagnostic Laboratories
- 9.5.3 Reference Laboratories
- 9.5.4 Academic & Research Institutes
- 9.5.5 Public Health Laboratories